Cargando…
Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer
The precise mechanism of resistance to anti-cancer drugs such as platinum drugs is not fully revealed. To reveal the mechanism of drug resistance, the molecular networks of anti-cancer drugs such as cisplatin, carboplatin, oxaliplatin, and arsenic trioxide were analyzed in several types of cancers....
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671144/ https://www.ncbi.nlm.nih.gov/pubmed/38003016 http://dx.doi.org/10.3390/genes14112073 |
_version_ | 1785149381516722176 |
---|---|
author | Tanabe, Shihori Boonstra, Eger Hong, Taehun Quader, Sabina Ono, Ryuichi Cabral, Horacio Aoyagi, Kazuhiko Yokozaki, Hiroshi Perkins, Edward J. Sasaki, Hiroki |
author_facet | Tanabe, Shihori Boonstra, Eger Hong, Taehun Quader, Sabina Ono, Ryuichi Cabral, Horacio Aoyagi, Kazuhiko Yokozaki, Hiroshi Perkins, Edward J. Sasaki, Hiroki |
author_sort | Tanabe, Shihori |
collection | PubMed |
description | The precise mechanism of resistance to anti-cancer drugs such as platinum drugs is not fully revealed. To reveal the mechanism of drug resistance, the molecular networks of anti-cancer drugs such as cisplatin, carboplatin, oxaliplatin, and arsenic trioxide were analyzed in several types of cancers. Since diffuse-type stomach adenocarcinoma, which has epithelial–mesenchymal transition (EMT)-like characteristics, is more malignant than intestinal-type stomach adenocarcinoma, the gene expression and molecular networks in diffuse- and intestinal-type stomach adenocarcinomas were analyzed. Analysis of carboplatin revealed the causal network in diffuse large B-cell lymphoma. The upstream regulators of the molecular networks of cisplatin-treated lung adenocarcinoma included the anti-cancer drug trichostatin A (TSA), a histone deacetylase inhibitor. The upstream regulator analysis of cisplatin revealed an increase in FAS, BTG2, SESN1, and CDKN1A, and the involvement of the tumor microenvironment pathway. The molecular networks were predicted to interact with several microRNAs, which may contribute to the identification of new drug targets for drug-resistant cancer. Analysis of oxaliplatin, a platinum drug, revealed that the SPINK1 pancreatic cancer pathway is inactivated in ischemic cardiomyopathy. The study showed the importance of the molecular networks of anti-cancer drugs and tumor microenvironment in the treatment of cancer resistant to anti-cancer drugs. |
format | Online Article Text |
id | pubmed-10671144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106711442023-11-13 Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer Tanabe, Shihori Boonstra, Eger Hong, Taehun Quader, Sabina Ono, Ryuichi Cabral, Horacio Aoyagi, Kazuhiko Yokozaki, Hiroshi Perkins, Edward J. Sasaki, Hiroki Genes (Basel) Brief Report The precise mechanism of resistance to anti-cancer drugs such as platinum drugs is not fully revealed. To reveal the mechanism of drug resistance, the molecular networks of anti-cancer drugs such as cisplatin, carboplatin, oxaliplatin, and arsenic trioxide were analyzed in several types of cancers. Since diffuse-type stomach adenocarcinoma, which has epithelial–mesenchymal transition (EMT)-like characteristics, is more malignant than intestinal-type stomach adenocarcinoma, the gene expression and molecular networks in diffuse- and intestinal-type stomach adenocarcinomas were analyzed. Analysis of carboplatin revealed the causal network in diffuse large B-cell lymphoma. The upstream regulators of the molecular networks of cisplatin-treated lung adenocarcinoma included the anti-cancer drug trichostatin A (TSA), a histone deacetylase inhibitor. The upstream regulator analysis of cisplatin revealed an increase in FAS, BTG2, SESN1, and CDKN1A, and the involvement of the tumor microenvironment pathway. The molecular networks were predicted to interact with several microRNAs, which may contribute to the identification of new drug targets for drug-resistant cancer. Analysis of oxaliplatin, a platinum drug, revealed that the SPINK1 pancreatic cancer pathway is inactivated in ischemic cardiomyopathy. The study showed the importance of the molecular networks of anti-cancer drugs and tumor microenvironment in the treatment of cancer resistant to anti-cancer drugs. MDPI 2023-11-13 /pmc/articles/PMC10671144/ /pubmed/38003016 http://dx.doi.org/10.3390/genes14112073 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Tanabe, Shihori Boonstra, Eger Hong, Taehun Quader, Sabina Ono, Ryuichi Cabral, Horacio Aoyagi, Kazuhiko Yokozaki, Hiroshi Perkins, Edward J. Sasaki, Hiroki Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer |
title | Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer |
title_full | Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer |
title_fullStr | Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer |
title_full_unstemmed | Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer |
title_short | Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer |
title_sort | molecular networks of platinum drugs and their interaction with micrornas in cancer |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671144/ https://www.ncbi.nlm.nih.gov/pubmed/38003016 http://dx.doi.org/10.3390/genes14112073 |
work_keys_str_mv | AT tanabeshihori molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer AT boonstraeger molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer AT hongtaehun molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer AT quadersabina molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer AT onoryuichi molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer AT cabralhoracio molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer AT aoyagikazuhiko molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer AT yokozakihiroshi molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer AT perkinsedwardj molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer AT sasakihiroki molecularnetworksofplatinumdrugsandtheirinteractionwithmicrornasincancer |